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Raal@wits.ac.za (F.J. Raal), barry@cdecentre.co.za (B.I.Background: Type 1 diabetes (T1DM) in sub-Saharan Africans is rare and is associated with high mortality
from nephropathy. We studied the prevalence and potential risk factors for microalbuminuria (MA) in
African and in age-of-onset matched white patients with T1DM. Risk factors for MA were evaluated pro-
spectively in an African cohort.
Materials and Methods: 68 African and 134 white patients, age at diagnosis 10–40 years, duration of dia-
betes > 2 years, were evaluated for MA; 48 Africans were followed prospectively.
Results: Africans had shorter duration of diabetes (median, 8 years vs 11 years), higher HbA1c (10.62(SD
2.52)%, vs 9.02(2.44)%, lower cholesterol (4.45(1.04) vs 5.45(1.16)mmol/l), and fewer (23.5% vs 54.5%) had
adolescent diabetes onset (p 0.0030 for each); the prevalence of MA was 39.7% and 24.6% respectively
(p = 0.0155). In multiple regression analysis MA was associated with mean HbA1c (p < 0.0001), younger
age at diagnosis (p = 0.0060), SBP (p = 0.0012) and African race (p = 0.0287). Prospectively, Africans devel-
oping MA (45%) had higher mean HbA1c levels (p = 0.0001), were more likely to have had adolescent
onset of DM (33.3% vs 8.0%, p = 0.0310) and lower BMI (p = 0.0340); logistic regression revealed that
higher HbA1c and SBP, and lower BMI predicted MA. Nine of 16 African subjects progressed to macroal-
buminuria; they were characterised only by extremely poor glycaemic control (mean HbA1c,
13.49(2.00)%).
Conclusions: Microalbuminuria, and severe hyperglycaemia, are common in diabetic Africans with short
duration TIDM; MA may rapidly progress to macroalbumiuria. African race may be associated with
increased susceptibility to diabetic nephropathy.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction duration of disease, poor glycaemic control, blood pressure, lipids,Type 1diabetes (T1DM) is relatively rare in sub-Saharan Africans,
especially in young children– the peak age of onset is about a decade
older than in white Europeans [1–3]. Although data are limited,
available information indicates that the prognosis in T1DM is poor
in Africa, as a result of both acute and long-term complications
[2,4]. Diabetic nephropathy appears to be particularly frequent in
diabetic Africans and is a major cause of morbidity and mortality
[4–6], perhapsmore so than in comparable populations of European
extraction; no comparative data have been published. Micro-albu-
minuria (MA) is a marker of early diabetic renal disease and is a
precursor of overt diabetic nephropathy, although it may regress
in a substantial proportion of patients [7]. Inﬂuences on and risk fac-
tors for the development of early diabetic nephropathy or its pro-
gression in T1DM include gender, age of onset of diabetes,ellitus. Published by Elsevier Ltd.
nology Unit, Musgrove Park
rset, UK. Tel.: + 44 0 1823
oo.com (W.J. Kalk), Fredrick.
Joffe).
Ocentral obesity and psychosocial and genetic factors [7–20]. The
great majority of patients studied have been of European extraction
and publications on renal involvement in T1DM from Africa are few
and cross-sectional [2,4,22]. Moreover, uncertainty remains about
some potential risk factors, notably the roles of blood pressure and
dyslipidaemia in the genesis ofMA.Wehave, therefore, investigated
the prevalence of early diabetic nephropathy and some associations
in a groupofAfricanpatientswithTIDMinurbanSouthAfrica, a pop-
ulation in epidemiological transition and characterised by relatively
lowserum lipid concentrations; anagematchedwhitepatient group
from the same institution was studied by way of comparison. In a
subgroup of Africans, the incidence of and potential risk factors for
MA and for progression to macro-albuminuria were evaluated in a
prospectively studied cohort.2. Subjects and methods
Patients attending the Diabetes Service at the Johannesburg
Academic Hospital, South Africa, between 1994 and 2008, with
age at diagnosis of diabetes 640 years, were studied. Africanpen access under CC BY-NC-ND license.
Table 1
The clinical and laboratory characteristics of all patients with type 1 diabetes and in the African and White subjects separately, excluding those with overt nephropathy. Data are
expressed as mean (SD) or median (IQR).
All subjects (n = 202) African (n = 68) White (n = 134) p
% male 60.4 55.9 62.7 0.459
Age (years) 34.7 (10.2) 34.9 (8.6) 34.6 (11.0) 0.844
Age diagnosis 22.5 (8.1) 26.2 (7.3) 20.6 (8.0) <0.0001
Adolescent onset (%) 44.1 23.5 54.5 <0.0001
Duration DM 9.0 (5.0,15.3) 8.0 (4.0,11.0) 11.0 (6.0,18.0) 0.0003
BMI 24.3 (4.3) 24.6 (3.9) 24.0 (4.7) 0.408
Hypertension (%) 29.2 33.8 26.9 0.304
SBP 121.1 (14.1) 119.3 (14.4) 121.3 (15.3) 0.367
DBP 76.0 (8.8) 76.9 (9.5) 75.5 (8.4) 0.290
Smokers (%) (n = 165) 39.0 31.3 43.1 0.115
HbA1c (%) 9.56 (2.57) 10.62 (2.52) 9.02 (2.44) <0.0001
Cholesterol (mmol/l) 5.09 (1.21) 4.45 (1.04) 5.42 (1.16) <0.0001
LDL-C (mmol/l) (n = 128) 3.03 (1.03) 2.50 (0.82) 3.34 (1.03) <0.0001
HDL-C (mmol/l) (n = 79) 1.30 (0.42) 1.31 (0.41) 1.43 (0.42) 0.114
Trigycerides(mmol/l) (n = 133) 1.00 (0.80,1.58) 0.90 (0.70,1.20) 1.10 (0.90,1.80) 0.0026
Creatinine (umol/l) 88.0 (81.0, 98.0) 87.0 (79.0,96.0) 89.5 (81.8,99.0) 0.092
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enous African names; several ‘tribal’ afﬁliations and ﬁrst languages
were included; all were born in southern Africa. White patients
were those of northern and southern European extraction. None
of the patients had known genetic admixtures. Type 1 diabetes
was diagnosed according to ADA criteria [23]. All subjects had
symptomatic hyperglycaemia at their diagnosis; many presented
with keto-acidosis. All were considered to be ‘ketosis-prone’, and
all required insulin therapy from diagnosis. Because the precise
classiﬁcation of diabetes in adult Africans can be difﬁcult [23] as
type 2 diabetes may commonly present with keto-acidosis [24];
among the African subjects aged 31–40 years at diagnosis, only
those who presented acutely, required insulin continuously from
diagnosis and/or were positive for antibodies against glutamic acid
decarboxylase (GAD-65 antibodies) [25] were accepted as having
T1DM. As persistent abnormal urinary albumin excretion seldom
occurs before two to three years of diabetes, only patients with
duration of diabetes of more than two years were included in the
analyses. Blood pressure (BP) was assessed with the subjects
seated after at least ﬁve minutes rest; large cuffs were used for ob-
ese patients. Pre-existing hypertension was diagnosed in the ab-
sence of prior abnormal urinary albumin excretion if the systolic
BP (SBP) was consistently P140 mmHg systolic and/or diastolic
BP (DBP) P90 mmHg or in individuals treated for hypertension.
Hypertensive patients were treated with angiotensin converting
enzyme inhibitors and diuretics, usually both in the African sub-
jects, with the addition of calcium channel blockers as third line
agents, in accordance with local protocols. HMG-Co A reductase
inhibitors (statins) were used only in the later part of the study;
cholesterol data included statin treated patients. Obesity was eval-
uated by body mass index (BMI; mass kg/height m2). Subjects were
classiﬁed as smokers if they were current or past users of tobacco.
Urinary albumin excretion was assessed from urine albumin:creat-
inine ratio measurements (ACR, mg/mmol); MA was deﬁned as an
ACR >2.5 mg/mmol in males or >3.5 mg/mmol in females in at least
two of three urine collections, and macro-albuminuria – overt
nephropathy – was deﬁned as an ACR P30 mg/mmol. Since the
day-to-day variability of urinary albumin excretion is some 50%,
for patients who provided only a single urine specimen urinary
ACRs P5.0 mg/mmol and P7.0 mg/mmol for men and women,
respectively (i.e., double the conventional cut-points) were used
to deﬁne MA. The methods for HbA1c (DCCT linked), serum lipids
and creatinine, urinary albumin and creatinine measurements
have been described previously [26]. Mean values for blood pres-
sure, HbA1c and total cholesterol prior to the onset of MA, or until
the end of follow-up in those with normal ACR, were used in the
analyses of putative risk factors.Data are expressed as a mean (SD) or median (inter-quartile
range – IQR) for variables with a skewed distribution. Differences
between groups were evaluated by the unpaired T-test or the
Mann Whitney U-test and the Chi squared test. Multiple and logis-
tic regression analyses were used to assess the independent asso-
ciations of putative risk factors with MA.
The study was approved by the Committee for Research on Hu-
man Subjects of the University of Witwatersrand.
3. Results
Ninety-one African patients with type 1 diabetes attended at
least once during the study period. Of these, 78(85.7%) had both
a duration of diabetes greater than 2 years and at least one urinary
ACR measurement; 10(12.8%) had macro-albuminuria when ﬁrst
evaluated and were, therefore, excluded. Thus, 68 patients with
duration >2 years were available for analyses for the prevalence
of MA. The youngest age at diagnosis of diabetes among the Afri-
cans was 10 years; therefore, only white patients aged 10–40 years
at diagnosis of T1DM attending during the same period were in-
cluded in the comparative analyses (n = 134).
Micro-albuminuria was signiﬁcantly more prevalent in African
than in white patients – 39.7% and 24.6%, respectively
(p = 0.0155), despite a shorter median duration of diabetes (8.0
vs 11.0 years respectively) and similar blood pressures and preva-
lence of pre-existing hypertension in each group. Blood pressure in
hypertensive subjects was higher than in those with normotension,
but hypertension was reasonably well controlled (hypertensive pa-
tients, 131.4/80.0 vs 116.2/74.3 mmHg in normotensive subjects;
p < 0.001 for both). Other group differences include proportion-
ately fewer African patients with diagnosis during adolescence
(age 10–20 years), higher mean levels for HbA1c but lower total
and LDL cholesterol and triglyceride concentrations (Table 1). Data
on African and white patients without and with MA are shown in
Table 2. Among the African subjects, those with MA were charac-
terised by a signiﬁcantly higher BP, mean HbA1c and cholesterol
levels and lower BMI; more patients with MA (32% vs 17%,
p = 0.161) had adolescent onset of diabetes. Among white patients,
the presence of MA was associated with female gender, younger
age at diagnosis and more frequent adolescent onset, a higher
prevalence of hypertension and higher SBP and higher HbA1c. Mul-
tiple regression analysis of all patients, after incorporating all mea-
surements signiﬁcantly different in the univariate analyses as the
independent variables revealed signiﬁcant independent associa-
tions between MA and younger age at the onset of diabetes
(p = 0.0060), higher HbA1c (p < 0.0001) and SBP (p = 0.0012), the
presence of pre-existing hypertension (p = 0.0068), lower BMI
Table 2
Comparison of variables in African and White patients without (MA ()) and with micro-albuminuria (MA (+)). Data are expressed as mean (SD) or median (IQR). Categories
marked with an asterisk (*) indicate signiﬁcant differences between African and White patients with mico-albuminuria.
Urine ACR African White
MA () (n = 40) MA (±) (n = 28) p MA () (n = 101) MA (±)(n = 33) p
Males (%) 52.5 60.7 0.203 70.3 39.4 0.0014
Age (years) 35.4 (7.9) 34.1 (9.6) 0.527 35.1 (10.5) 33.1 (12.3) 0.368
Age at diagnosis (years) 27.0 (6.5) 25.0* (8.3) 0.286 22.1 (7.5) 16.3* (7.2) 0.0002
Adolescent onset (%) 17.5 32.1* 0.161 47.5 75.7* 0.0047
Duration (years) 8.5 (4.0, 11.8) 7.5* (4.0, 9.8) 0.760 11.0 (6, 17) 12.0* (7, 23) 0.190
BMI 25.6 (4.1) 23.1 (3.0) 0.0126 24.1 (4.0) 23.9 (6.0) 0.914
Hypertension (%) 27.5 42.9 0.301 20.8 45.5 0.0055
Systolic BP 115.6 (13.3) 124.6 (14.6) 0.0109 119.1 (12.3) 128.3 (20.7) 0.0194
Diastolic BP 74.9 (8.3) 79.9 (10.5) 0.0317 75.2 (7.7) 76.4 (10.4) 0.5499
Smokers (%) 30.8 32.0 0.601 45.7 34.5 0.284
HbA1c (%) 9.55 (1.98) 12.14* (2.46) <0.0001 8.83 (2.22) 9.64* (2.96) 0.154
Cholesterol (mmol/) 4.23 (0.99) 4.76* (1.03) 0.0392 5.26 (1.09) 5.66* (1.36) 0.179
LDL-C (mmol/l) 2.40 (0.76) 2.64 (0.91) 0.341 3.30 (1.03) 3.51* (1.03) 0.450
HDL-C (mmol/l) 1.26* (0.37) 1.39 (0.45) 0.251 1.42 (0.44) 1.50 (0.38) 0.518
Triglyceride (mmol/l) 0.90 (0.7,1.3) 0.90 (0.7,1.2) 0.704 1.10 (0.9, 1.8) 1.25 (0.9,2.0) 0.916
Creatinine (umol/l) 86.0 (78, 95) 90.5 (79,98) 0.248 90.0 (81,99) 88.0 (82,104) 0.939
* Signiﬁcant differences between the African and white patients with MA (p < 0.05).
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for the duration of diabetes increased the signiﬁcance of the asso-
ciations (R2 = 0.3717). Regression analysis was carried out sepa-
rately for each group. In the African group, signiﬁcant
independent associations were found between the presence of
MA and higher HbA1c and (p < 0.0001) SBP (p = 0.0195) and prior
hypertension (p = 0.0348) and lower BMI (p = 0.0022),
(R2 = 0.4617). In the white patients, there were signiﬁcant indepen-
dent associations between MA and female gender (p = 0.0002),
younger age at diagnosis (p < 0.0001), higher systolic BP
(p = 0.0144) and hypertension (p = 0.0477) (R2 = 0.2925). Compari-
sons between subjects with MA revealed group differences in gen-
der, age at diagnosis, duration of diabetes at the onset of MA
(medians, African 6.0 years, white subjects 12.0 years) and HbA1c
and total cholesterol concentrations.
In order to evaluate possible differences in susceptibility to re-
nal damage between the races from very severe long term hyper-
glycaemia, we compared the prevalence of MA in the total
African group and in the subset of white patients whose HbA1c
was greater than the group median (>8.73%; n = 68; mean HbA1c,
10.89(1.89)%, vs 10.58(2.55)% in the African group, p = 0.4288).
As in the total white group, in comparison with the Africans, this
subgroup was characterised by signiﬁcantly younger age at diag-
nosis and longer median duration of diabetes – 11.0 vs 8.0 years
in the Africans (p = 0.0009). The prevalence of MA was 30.9%, vs
40.3% in the Africans (p = 0.253). Among patients with MA, the
duration of diabetes was greater in the white subgroup –
12.0 years, vs 7.0 years in the Africans (p = 0.0007). All other vari-
ables were similar in these MA-positive groups, except, again, the
younger age at the onset in the white subjects. Multiple regression
analysis, with the presence of MA as the dependent variable in the
combined white subgroup and Africans revealed signiﬁcant associ-
ations between the development of MA and HbA1c (p < 0.0001),
SBP (p = 0.0003) young age at diagnosis of diabetes (p = 0.0010)
and African race (p = 0.0020).
Since the development of diabetic microvascular complications
is a function of the duration of diabetes and average long-term gly-
caemic control (8, 9), the total ‘glycaemic exposure’ prior to the on-
set of MA was calculated as [mean HbA1c x duration of diabetes]
prior to the onset of MA: in the white subgroup, 140(95, 197)
HbA1c.years and in the Africans 82(51, 132) HbA1c.years
(p = 0.0126).
Forty-eight African subjects had sufﬁcient longitudinal data
suitable for the analysis of potential risk factors for MA (duration8.0(4.0, 11.3) years). Their characteristics were similar to those of
the larger African group and 70% had documented acute onset of
diabetes. Anti-GAD-65 antibodies were detected, some years after
diagnosis, in 11 of the 21(59%) who were tested; the insulin dose at
the end of follow-up was 0.72(0.63, 1.00) U/kg. In this cohort 21
subjects (45%) developed persistent micro-albuminuria (excluding
two subjects who had clearly documented transient micro-albu-
minuria): prior to the onset of MA, they were characterised in com-
parison to those who remained free of persistent MA, by higher
mean levels of HbA1c (12.41(2.06)% vs 9.62(2.25)%, p = 0.0001)
and mean total cholesterol (4.77(0.97) vs 3.86(0.61)mmol/l,
p = 0.0008) and lower BMI (22.6(2.8) vs 26.4(3.9), p = 0.0340) and
they were more likely to have developed diabetes during adoles-
cence (33.3% vs 8.0%, p = 0.0310); all other variables measured,
including blood pressures, duration of DM and renal function were
similar. Logistic regression analysis, with the development of MA
as the dependent variable, and all parameters signiﬁcantly differ-
ent in the univariate analyses entered as independent variables,
demonstrated that the independent predictors of MA in these Afri-
can patients were higher levels of mean HbA1c (p = 0.007, odds ra-
tio (OR, 95% CI) 2.98 (1.35–6.60)), higher mean SBP (p = 0.038; odds
ratio 1.16(1.01–1.33), and lower BMI (p = 0.012; OR 0.59(0.39–
0.89)). Further follow-up data on urinary ACR were available in
16 patients who had developed persistent MA. Micro-albuminuria
progressed to macro-albuminuria (ACR > 30 mg/mmol) in nine
subjects with median duration of MA of 3.0 years (range 1–5 years)
and total duration of diabetes of 8.0 years (range 4–16 years); in
the remaining seven patients MA persisted for a median of
3.0 years (range 1–6 years) with total duration of diabetes of
10.0 years (range 4–24 years). The mean HbA1c level in those
who progressed to macro-albuminuria was 13.49(2.00)%, and
11.38(1.62)% in subjects with persistent MA during follow-up
(p = 0.040); other parameters were similar.4. Discussion
The clinical variables in the African and white patient groups
were generally well matched – for age, BMI, prevalence of hyper-
tension, BP and renal function, with an unexpected male predom-
inance in both groups. A substantial proportion of the white
patients attending our clinic who had an age of the onset of diabe-
tes <10 years were not included in the analyses so as to reduce the
possible bias of the longer duration of pre-adolescent diabetes
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much younger in the white group, reﬂecting the low rate of adoles-
cent onset in the Africans [3]. The major additional group differ-
ences were the strikingly worse glycaemic control in the African
patients and their lower lipid levels, anticipated from the general
African population [29]. In the white group, the mean HbA1c was
similar to those reported from several European and North Amer-
ican studies [7,11,15,18], while in the Africans, it was much higher,
although comparable to levels in some European centres [30].
The prevalence of MA was signiﬁcantly greater in the African
(40%) than in the white patients (25%), despite a 50% shorter dura-
tion of diabetes prior to the onset of MA in the former, raising the
possibility of a greater predisposition among this population. In-
deed, African race was independently associated with the develop-
ment of MA. Other risk factors, such as poor glycaemic control,
blood pressure, female gender and younger age at diagnosis are
common to previous reports. Micro-albuminuria was also more
prevalent than recently reported from Tanzania but the duration
of diabetes was shorter in that study [21].
When the two race groups were evaluated separately, some
similarities and differences in risk factors were observed. In both
groups, MA was associated with higher blood pressures and worse
glycaemic control and in the Africans also with lower BMI and
higher total cholesterol concentrations, which were, however, low-
er than in the MA-positive white patients. In the white group MA
was also associated with younger age at diagnosis and female gen-
der [15,16] but not with cholesterol or triglyceride concentrations.
In neither group was duration of diabetes associated with MA,
probably because of the short duration of follow-up.
So as to offset the strikingly worse long-term glycaemic control
in the Africans, we repeated the group comparisons after excluding
the best controlled white patients – those with mean HbA1c less
than the median (68.73%). Mean HbA1c levels in this very poorly
controlled white subgroup were close to those in the Africans.
The prevalence of MA remained higher in the African group (40%
vs 31% in the white subgroup); however, the duration of diabetes
was substantially shorter in the African subjects. Thus, the esti-
mated total exposure to similar severe hyperglycaemia was signif-
icantly lower in the African patients for a comparable prevalence of
MA, suggesting greater renal susceptibility to hyperglycaemia.
Regression analysis supported this possibility, in that among these
patients with similar degrees of hyperglycaemia, the African race
remained a (more) signiﬁcant independent predictor of MA; other
signiﬁcant associations are well known.
The incidence of MA in the smaller longitudinally studied Afri-
can cohort was similarly high, at 45%, (median duration 8 years),
comparable to a 6-year development of any proteinuria recently
reported in African Americans with TIDM [19]. In keeping with
the cross-sectional analysis, independent predictors for the devel-
opment of MA had a higher mean HbA1c and mean SPB and lower
BMI.
Racial differences in the apparent susceptibility to diabetic
nephropathy have been noted before. African-Americans with type
1 diabetes exhibited earlier onset and a greater age-speciﬁc inci-
dence of end stage renal disease than white patients [31]; similar
patterns were noted in patients with type 2 diabetes. Recent anal-
yses, mainly in type 2 diabetes, have identiﬁed genes which are
closely associated with diabetic nephropathy, some of which may
predispose to, and others which may protect against this complica-
tion [32,33]. While some genomic regions underlying nephropathy
susceptibility are common to the several populations studied, oth-
ers appear to be more race-speciﬁc, notably between African and
European Americans [32]. Moreover, genes which are ‘protective’
in European Americans may not exert this effect in African Amer-
icans [33]. Studies in white patients, however, suggest that the ge-
netic basis for nephropathy may be different in type1 and type 2diabetes [34]; inter-ethnic genetic studies are awaited. Apart from
African-derived populations, others with type 1 diabetes may also
be at increased risk for nephropathy in comparison to patients of
European extraction [35].
In type 1 diabetes, poor glycaemic control has been observed to
be a consistent indicator of risk for MA, proportional to the average
degree of hyperglycaemia [8,30]. Among our African subjects mean
HbA1c was also the strongest independent risk factor for progres-
sion to MA; indeed, 73% had a mean HbA1c above 9.0%, a level
strongly associated with the development of early diabetic renal
disease in young white patients [36]. This high incidence of MA
was comparable to the 10 year incidence among the worst con-
trolled (HbA1c > 8.6%) Danish patients after some 10 years of dia-
betes [11].
Although mean blood pressures in the African patients were
mainly normal, a higher systolic BP predicted the onset of MA
[9,17]. It has been postulated that among white diabetic subjects,
slightly elevated blood pressures may interact with hyperglyca-
emia [37] and perhaps a genetic predisposition [20], to cause glo-
merular injury. Furthermore, there may be patient subgroups with
abnormal renal vulnerability to small increments in blood pressure
[38]. In urban African populations, in comparison with those of
European extraction, hypertension occurs more frequently, starts
earlier and appears to have greater harmful effects on the kidneys
[39], possibly mediated via differences in renal sodium handling
and lower renin concentrations [40]. Thus, it is plausible that there
may be racial differences in renal susceptibility to small elevations
in blood pressure in the presence of hyperglycaemia or to hyper-
glycaemia per se. In type 1 diabetic African Americans, systolic BP
was also a risk factor for progression to proteinuria [19]. In some
European cohorts, however, a rise in blood pressure has been found
only some years after the onset of MA [41], a pattern observed in
an early analysis from our unit in young white patients [42].
Dyslipidaemias have been cited as potential risk factors for MA
in Type 1 diabetes [10,14,17,18]. In our African patients, total and
LDL-cholesterol and triglyceride concentrations were relatively
low, similar to those in the non diabetic African population and
lower than in the local white population [29]. Although MA-posi-
tive African patients had higher levels, cholesterol was not inde-
pendently associated with MA – concentrations that correlated
signiﬁcantly with HbA1c (r = 0.4595, p = 0.0010). Furthermore, nei-
ther triglycerides nor HDL cholesterol concentrations were associ-
ated with MA in either group. Of note is the observation that the
relatively low lipid levels in the Africans did not appear to protect
against MA.
Increased BMI or waist circumference and elevated triglycerides
are features of metabolic syndrome, which are said to be risk fac-
tors for nephropathy [18]. Paradoxically, in our African group, low-
er BMI appeared to be an independent predictor of MA. While it is
unlikely that relative leanness is itself a risk factor, it may correlate
with some other unmeasured factors, possibly social or economic,
in this deprived population [43] or with low adherence to pre-
scribed insulin doses. In our African patients, neither the intensity
of insulin therapy nor total prescribed daily insulin doses inﬂu-
enced glycaemic control or the development of MA.
Signiﬁcant hyperglycaemia appears to promote the progression
of MA to macro-albuminuria [7,11]. In the African subjects fol-
lowed after the onset of persistent MA, macro-albuminuria devel-
oped after 1–5 years in more than half, despite documented
therapy with angiotensin converting enzyme inhibitors. These pa-
tients were characterised by extremely poor average glycemic con-
trol (mean HbA1c, 13.49%). Rapid progression from normo- to
macro-albuminuria has also been documented in type 1 diabetic
African Americans [19].
A limitation of this study is the relatively small number of Afri-
can patients studied longitudinally and some gaps in the data col-
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tion in sub-Saharan Africa and prospective data collection is difﬁ-
cult in this mobile population in South Africa [5,23], often
characterised by erratic clinic attendance. Gaps in data collection
might have lead to misclassiﬁcation in some subjects, especially
those with transient MA, which appeared to be infrequent, and
over-estimation of the real prevalence and incidence of MA. The
use of a higher ACR cut point to deﬁne MA should have reduced
this problem. It is also possible that our data may have been biased
as a consequence of early mortality from acute metabolic compli-
cations [2,5,23,24]. Lastly, our patients may not be representative
of all type 1 diabetic patients in the country, as our hospital’s dia-
betes service was relatively well endowed in comparison with
smaller centres [44,45]. On the other hand, the potential strengths
of our analyses lie in the use of multiple measurements obtained at
patients’ annual reviews, prior to the onset of MA. Furthermore,
the associations we observed with the development of MA were
statistically strong and were mainly similar to previous reports.
Notably, severe chronic hyperglycaemia was a feature of our
African patients, despite routine care which included skilled diabe-
tes nurse specialists/educators ﬂuent in the indigenous African lan-
guages. Comparable levels of hyperglycaemia and a high
prevalence of early diabetic complications have been noted re-
cently in other transitional peoples, such as Maori and Paciﬁc
Islanders [46] and in young adult African Americans [47]. Detailed
information on the type of insulin therapy was available in 37 pa-
tients: 22 received twice daily biphasic injections and 15 intensive
basal bolus treatments. Intensity of therapy did not inﬂuence the
risk of developing MA (intensive therapy in eight of 17 with MA;
seven of 20 without MA); the daily insulin doses prescribed were
also similar in each group (MA-positive, 0.72 U/kg; MA-negative,
73 U/kg). Inﬂuences on glycaemic control, such as poverty, depres-
sion and psychosocial issues [19,46,48,49] may be more prevalent
in transitional communities. Thus for Africans with type 1 diabetes,
there is undoubtedly a special need for the provision of holistic dia-
betes services aimed at reducing their high rates hyperglycaemia,
complications and premature death [2,5]. There is accumulating
evidence that improved routine services can lead to better out-
comes in type 1 diabetic population [50].
In conclusion, we have found a high incidence of micro-albu-
minuria among Africans with type 1 diabetes predicted primarily
by their extremely poor glycaemic control but possibly also related
to an increased susceptibility to diabetic glomerular injury. Recog-
nition of their high incidence of diabetic renal disease, its early on-
set and potential for rapid progression should improve their
prognosis.Duality of interest
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